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Changes in chromatin structure mediated by ATP-depen-
dent nucleosome remodelers and histone modifying
enzymes are integral to the process of gene regulation.
Here, we review the roles of the SWI/SNF (switch/sucrose
nonfermenting) and NuRD (nucleosome remodeling and
deacetylase) and the Polycomb system in chromatin regu-
lation and cancer. First, we discuss the basic molecular
mechanism of nucleosome remodeling, and how this con-
trols gene transcription. Next, we provide an overview of
the functional organization and biochemical activities of
SWI/SNF, NuRD, and Polycomb complexes. We describe
how, in metazoans, the balance of these activities is cen-
tral to the proper regulation of gene expression and cellu-
lar identity during development. Whereas SWI/SNF
counteracts Polycomb, NuRD facilitates Polycomb
repression on chromatin. Finally, we discuss how disrup-
tions of this regulatory equilibrium contribute to onco-
genesis, and how new insights into the biological
functions of remodelers and Polycombs are opening ave-
nues for therapeutic interventions on a broad range of can-
cer types.
Chromatin is fundamental to all processes involving the
eukaryotic genome. The nucleosome—147 bp of DNA
wrapped tightly in ∼1.7 left-handed superhelical turns
around an octamer of histones H2A, H2B, H3, and H4—
is the fundamental repeating unit of chromatin. The
need to compact genomic DNA (∼2 m for the human ge-
nome) to fit into the cellular nucleus (with a diameter of
only ∼10 µm) is often presented as the rationale for nucle-
osomes.However, the packing fraction ofDNAwithin the
nucleus of a somatic cell is typically only about 1%, leav-
ing ample unoccupied space. Therefore, rather than solv-
ing a physical packaging problem, nucleosomes instead
provide a functional organization of the genome, enabling
regulation of its replication, repair, and transcription. In
fact, the most pertinent consequence of packaging geno-
mic DNA into chromatin is that nucleosomes can impede
access of DNA-binding proteins, such as transcription fac-
tors. Consequently, chromatin remodeling constitutes a
fundamental level of gene expression control.
Central to chromatin organization, ATP-dependent
chromatin remodeling enzymes (remodelers) are molecu-
lar motors dedicated to the assembly, positioning, or dis-
ruption of nucleosomes (Becker and Workman 2013;
Clapier et al. 2017). By modulating the presentation of
DNA, chromatin remodelers provide a fundamental level
of gene expression control. In addition, chromatin state
is regulated through a plethora of potranslational modifi-
cations, in particular of the unstructured N-terminal his-
tone tails that protrude from the nucleosome (Zentner
and Henikoff 2013; Allis and Jenuwein 2016). These mod-
ifications, when present at specific residues on the histone
N-terminal tails, can promote or antagonize the recruit-
ment of regulatory proteins and may directly affect the
compaction of the chromatin fiber. The local pattern of
histone modifications is closely correlated with the tran-
scriptional state of the associated gene or regulatory
DNA element. For example, histone acetylation is gener-
ally associated with active chromatin, irrespective of
which residue ismodified. In contrast, for histonemethyl-
ation, the specific residue that is modified determines
whether it is an active or a repressive mark. For example,
while methylation of histone H3 at Lys4 (H3K4) by the
MLL/COMPASSmethyltransferases is associatedwith ac-
tive transcription (Piunti and Shilatifard 2016), trimethy-
lation at Lys27 (H3K27me3) is central to gene silencing
by the Polycomb system (Schuettengruber et al. 2017). Al-
though remodelers and histone-modifying enzymes, such
asmembers of thePolycombgroup, catalyze fundamental-
ly different biochemical reactions, they function in an in-
tegrated manner to determine chromatin state. Here, we
reviewhowremodelers andPolycombsmodulate the chro-
matin template to regulate gene expression. We also[Keywords: NuRD; Polycomb; SWI/SNF; cancer; chromatin]Corresponding authors: c.verrrijzer@erasmusmc.nl, adrian.bracken@tcd.
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examine the interplay between the SWI/SNF (switch/
sucrose nonfermenting) andNuRD (nucleosome remodel-
ing anddeacetylase) remodelerswithPolycombs inhuman
cancer and how our expanding understanding of their biol-
ogy is guiding the development of new cancer treatments.
ATP-dependent DNA translocation drives nucleosome
remodeling
To understand how chromatin remodelers are powerful
regulators of gene transcription, it is first necessary to un-
derstand theirmechanisms of action. A chromatin remod-
eling reaction can have a variety of different outcomes
(Becker and Workman 2013; Clapier et al. 2017). Through
a slidingmechanism, a remodeler canmove a nucleosome
along the DNA template (Fig. 1A). Remodelers can gener-
ate a poorly understood remodeled state, in which the
DNA becomes more accessible, but the histone octamer
does not translocate to a new position. The action of
remodelers can also result in a partial disruption of the nu-
cleosome structure (e.g., through the eviction of a histone
H2A/H2B dimer), while some remodelers mediate the
exchange between histone variants. Finally, remodeling
can lead to the complete eviction of the histone octamer.
Whereas there are compelling examples of each of these
mechanisms, their relative importance in vivo remains
unclear. There are four major families of remodelers
named after their central ATPase: SWI/SNF, INO80,
ISWI, and CHD (Fig. 1B; Becker andWorkman 2013; Clap-
ier et al. 2017). Remodelers are further defined by unique
sets of associated proteins that canmodulate their activity
or recruitment to chromatin. The various remodelers per-
form a wide-range of mostly nonredundant functions in
themaintenance, transmission, and expression of eukary-
otic genomes (Becker and Workman 2013; Clapier et al.
2017). For example, CHD1 and the ISWI class ACF remod-
elers mediate the formation of regular nucleosomal ar-
rays, whereas SWI/SNF mediates their local disruption.
INO80 class remodelers catalyze the exchange between
the canonical histone H2A and the variant H2A.Z in
nucleosomes.
The basic action of the ATPase in different remodeling
complexes appears to be largely similar (Clapier et al.
2017). Here, we highlight the salient aspects of our current
understanding of remodeler function, in particular those
relevant for SWI/SNF and NuRD. All remodelers contain
a single motor subunit that belongs to the superfamily of
ATP-dependent DNA and RNA translocases and heli-
cases. The ATPase domain within the catalytic subunit
is split into two domains with homology to the ATPase
domain of the Escherichia coli RecA DNA-binding pro-
tein, referred to as lobes 1 and 2. The catalytic subunits
of remodelers contain class-specific domains that can
modulate their activity ormediate binding to DNA or his-
tones (Fig. 1B). The noncatalytic subunits of remodeler
complexes provide a plethora of additional functionalities,
including regulation of the ATPase, providing contacts
with DNA, histones, histone chaperones or sequence-spe-
cific transcription factors. A large body of studies on the
mechanisms and structures of remodelers engaged with
nucleosomes suggest a common mode of action. Funda-
mental to chromatin remodeling is the ATP-dependent
translocation of DNA along the histone core of the nucle-
osome (Saha et al. 2002; Whitehouse et al. 2003; Clapier
et al. 2017). Studies on classic translocases revealed that
theymove along one of theDNAstrands, named the track-
ing strand,while the other strand is referred to as the guide
strand (Fig. 2A). The ATPases of SWI/SNF, ISWI, and
CHD1 all bind to the nucleosomal DNA at superhelical
position 2 (SHL+2), which is located two helical turns
away from the nucleosomal dyad (Fig. 2B; Farnung et al.
A
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Figure 1. ATP-dependent chromatin remodeling (A) Different
outcomes of ATP-dependent remodeling of nucleosomes.
Remodeler action can drive the sliding of a nucleosome to anoth-
er position on the DNA, thus exposing a previously bound se-
quence. Alternatively, remodelers can make the nucleosomal
DNAmore accessible, while the histone octamer remains associ-
ated. Remodeling can also disrupt the octamer structure causing
a partial disassembly, typically through eviction of histone H2A/
H2B dimers. Specialized remodelers can mediate the exchange
between histone variants. Finally, remodeling can result in the
complete eviction of the histone octamer. (B) Structural domains
of the fourmajor Snf2ATPase subfamilies, SWI/SNF, CHD, ISWI,
and INO80. The translocase/ATPase domain of all remodelers
comprises two RecA-like lobes separated by an insertion (high-
lighted in gray). Members of the INO80 family have a longer in-
sertion than other remodelers. Each subfamily is characterized
by a unique set of additional domains, including the HSA (heli-
case SANT-associated) and post-HSA domains, SnAC (Snf2
ATP coupling), AT hooks (A/T-rich DNA-binding domains),
Bromo (bromodomains), Chromo (chromodomains), SANT-
SLIDE domain, PHD finger (plant homeodomain), HAND-
SANT-SLIDE domain, AutoN (autoinhibitory N-terminal), and
NegC (negative regulator of coupling). See the text for details
and references.
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2017; Liu et al. 2017; Sundaramoorthy et al. 2018; Li et al.,
2019; Yan et al., 2019). In the resting state, the two lobes
have an open conformation, separating the Walker A and
B motifs in lobe 1 from a crucial arginine in lobe 2. ATP
binding is accompanied by a conformational change (re-
ferred to as “closed state”) that creates a binding pocket
comprising theWalkerAandBmotifs in lobe 1and the cat-
alytic arginine in lobe 2. Following ATP hydrolysis, the
two lobes open up again, creating a cycle of ATP-binding
and hydrolysis that drives movement of the translocase
along the DNA tracking strand using an inchwormmech-
anism with a 1-bp step per ATP hydrolysis (Clapier et al.
2017; Li et al., 2019).However, nucleosome remodeling in-
volves additional contacts between the remodeler and the
nucleosome (Fig. 2C).These includebindingof theATPase
to the opposite DNA gyre and the histone core. In particu-
lar, an acidic patch formed by histones H2A and H2B is
frequently contacted by remodelers (Dann et al. 2017; Ga-
marra et al. 2018). Moreover, some remodelers interact
with theN-terminal tail of histoneH4or contain addition-
al DNA-binding domains that bind the linker DNA.
Binding to these additional sites fixes the translocase, pre-
venting it from walking along the nucleosomal DNA. In-
stead, the remodeler will now pull the DNA toward the
octamer dyad. This creates a ratcheting cycle in which
the DNA is locally distorted, and through a combination
of translational and rotational displacement peeled off
the histone core (Clapier et al. 2017; Li et al., 2019).
Throughout this remodeling process the histone core
does not appear to undergo a major deformation (Yan
et al., 2019). In summary, nucleosome remodeling depends
on ATP-dependent DNA translocation driven by a motor
domain that is fixed onto the nucleosome through addi-
tionalDNAandhistone contacts. Proteindomainsoutside
the RecA lobes play crucial roles in remodeler functional-
ity (Clapier et al. 2017). Finally, in most remodelers,
the ATPase is associated with accessory subunits that
determine remodeler function and targeting to specific ge-
nomic loci.
How chromatin remodelers regulate transcription
At its most basic level, remodelers control gene transcrip-
tion by mobilizing nucleosomes to make gene regulatory
elements more or less accessible to the transcription
machinery. Nucleosomes present a barrier for RNA poly-
merase II (RNAPII), and consequently there is no basal
transcription on chromatin templates. Rather, gene tran-
scription on chromatin requires sequence-specific tran-
scription factors, which use coregulators, including
remodelers, histone-modifying enzymes, and chaperones.
Different remodelers perform diverse, nonredundant
functions in the transcription cycle. Several ISWI class
remodelers function in the assembly and generation of
regularly spaced nucleosomal arrays (Fig. 3A). This plays
a crucial role in the packaging of newly synthesized
DNA following replication. Moreover, studies in yeast re-
vealed that the generation of evenly spaced nucleosomes
in gene bodies by ISWI and CHD1 remodelers helps to re-
press cryptic initiation of transcription (Becker andWork-
man 2013; Clapier et al. 2017). SWI/SNF remodelers have
been implicated in generating an open chromatin confor-
mation at gene promoters and enhancers (Fig. 3B). Induc-
tion of the unfolded protein response transcription
program in Drosophila cells caused extensive changes in
nucleosomal DNA accessibility, without accompanying
changes in nucleosome occupancy (Mueller et al. 2017).
Several studies suggested the presence of “fragile” nucle-
osomes, with DNA that is highly accessible, at regulated
promoters (Lai and Pugh 2017). A recent study showed
that these fragile nucleosomes are partially unwrapped
RSC remodeling intermediates, which result from cooper-
ation between RSC and general regulatory transcription
factors (Brahma and Henikoff, 2019). In addition to chang-
ing DNA accessibility through remodeling, remodelers
can also affect the composition of the histone core. For ex-
ample, the INO80 class remodelers mediate the replace-
ment of canonical histone H2A by the H2A.Z variant
(Clapier et al. 2017; Lai and Pugh 2017). H2A.Z containing
A
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Figure 2. Model of nucleosome remodeling. (A) Cartoon of a ge-
neric ATP-dependent translocase RecA lobe 1 and lobe 2 moving
along the tracking strand in a 3′ to 5′ direction. A cycle of ATP-
binding and hydrolysis drives conformational changes through
which the translocase “inchworms” along the tracking strand
with 1-bp steps per every ATP hydrolysis. (B) Top and side view
of remodeler ATPase binding to a nucleosome. The ATPase sub-
units of SWI/SNF, ISWI, CHD1, and SWR1 bind the nucleosomal
DNA at superhelical position 2 (SHL+2). (C ) Remodeler ATPases
make additional contacts through (1) binding to the opposite
DNA gyre,∼90 bp away; (2) contacting the histone core, typically
at an acidic patch formed by H2A and H2B; (3) binding the linker
DNA; and (4) interacting with theN-terminal tail of (usually) his-
tone H4. Due to these additional contacts, the ATPase does not
move along along the nucleosomal DNA, but rather pulls the
DNA toward the octamer dyad. Multiple cycles of ATP-binding
and hydrolysis generates a ratchetingmotion that locally distorts
the DNA and peels it off the histone core. See the text for details
and references.
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nucleosomes are enriched around transcription start sites
and increase accessibility of nucleosomal DNA.
A key mechanism of gene selectivity is the cooperation
between remodelers and sequence-specific DNA-binding
transcription factors. Remodeler recruitment can be re-
enforced by local chromatin changes. Histone acetylation
can promote the recruitment of SWI/SNF to specific loci
through recognition of acetylated histones by a bromo
domain (Becker and Workman 2013). As discussed below,
SWI/SNF and the Polycomb repressors function antago-
nistically on many regulatory DNA elements. The
NuRDcomplexes can oppose SWI/SNFat shared regulato-
ry elements (Fig. 3C). NuRD can generate repressive chro-
matin through nucleosome placement at regulatory DNA
elements and histone deacetylation. The Polycomb sys-
tem might further advance the formation of a repressive
chromatin environment through H3K27 methylation
and chromatin compaction (discussed below). It must be
stressed that the behavior of a substantial proportion of
promoters does not conform to generalizations derived
from averaging results from genome-wide studies, which
should be considered more as rules of thumb than as dog-
mas that apply to all genes.
Structural and functional diversification of SWI/SNF
remodelers
The large multisubunit SWI/SNF complex was the first
remodeler described and remains the best studied. SWI/
SNF was originally identified genetically in Saccharomy-
ces cerevisiae through screens for genes that were in-
volved in expression of the HO nuclease, required for
mating type switching (SWI) (Stern et al. 1984), and ex-
pression of the SUC2 invertase, required for sucrose fer-
mentation (SNF) (Neigeborn and Carlson 1984; Abrams
et al. 1986). Several of the encoded proteins, including
the Snf2 ATPase, turned out to reside in a common com-
plex, named SWI/SNF (Becker and Workman 2013; Clap-
ier et al. 2017). The observation that mutations in
histones alleviated the requirement for SWI/SNF and
changes in chromatin structure in snf2mutants, suggest-
ed that SWI/SNF functions through targeting chromatin
(Winston and Carlson 1992; Kruger et al. 1995). Indeed,
in vitro biochemical analysis of yeast SWI/SNF revealed
ATP-dependent chromatin remodeling and increased
DNA accessibility (Cote et al. 1994). These results sup-
ported a scenario in which SWI/SNF activity opens-up
promoter chromatin to promote transcriptional activa-
tion. Following the discovery of yeast SWI/SNF, related
complexes were identified in mammalian cells that per-
formed similar chromatin remodeling and gene regulatory
functions (Imbalzano et al. 1994; Kwon et al. 1994).
There are two main subtypes of SWI/SNF complexes
that are broadly conserved among eukaryotes (Fig. 4A; Ta-
ble 1). The first includes yeast SWI/SNF,Drosophila BAP,
and mammalian BAF, while the second class includes
yeast RSC, fly PBAP, and mammalian PBAF (Mohrmann
andVerrijzer 2005). The corresponding complexes contain
a variable number of identical subunits and paralogs that
form a common core, associated with a set of signature
subunits that are unique to either SWI/SNF-BAF or
RSC-PBAF. Sth1, the ATPase of RSC, is a paralog of
Snf2, the motor subunit of SWI/SNF. RSC and SWI/SNF
contain four additional paralogs and share three subunits.
The remaining subunits are unique for each complex.
Both complexes are involved in activation of RNAPII tran-
scription of largely nonoverlapping sets of genes and have
been implicated in different aspects of DNA repair. RSC is
also involved in RNA polymerase III transcription and
several nontranscriptional chromosomal functions
B
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Figure 3. Remodeler functions in organizing the chromatin
template. (A) Remodelers such as the ISWI class ACF mediate
the formation of regularly spaced nucleosomal arrays; e.g., follow-
ing DNA replication or other disruptions of chromatin organiza-
tion. Well-organized arrays help prevent spurious initiation of
transcription. (B) SWI/SNF remodelers promote transcription
activation by generating an open chromatin conformation at pro-
moters and enhancers, which may involve the sliding, displace-
ment, or restructuring of nucleosomes. The relative importance
of each of these mechanisms in vivo remains to be determined.
Remodeler targeting involves recruitment by sequence-specific
transcription factors and the local chromatin state; e.g., through
recognition of acetylated histones by one of the bromodomains
in SWI/SNF. In addition, SWI/SNF remodelers counteract Poly-
comb-repressive complexes (PRCs). (C ) NuRD remodelers antag-
onize SWI/SNF function. NuRD mediates nucleosome invasion
of regulatory DNA, and removal of acetylation marks. NuRD ac-
tivity is then thought to promote the subsequent recruitment of
the Polycomb system via its deacetylation of H3K27 and/or nu-
cleosome remodelling, to further the formation of repressive
chromatin. Green flags represent histone acetylation, and the
red flag represents H3K27me3.
Bracken et al.
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throughout the cell cycle (Clapier et al. 2017). Human
cells contain two distinct SWI/SNF ATPases, named
SMARCA4/BRG1 and SMARCA2/hBRM, which are
both equally related to yeast Swi2/Snf2 and Sth1. Either
ATPase associates with about eight additional subunits
to form a core complex shared by both BAF and PBAF. In
addition, there are two sets of mutually exclusive signa-
ture subunits that associate with the common core to
form either BAF or PBAF. Polybromo (PBRM1), BRD7,
ARID2, and PHF10 are specific for PBAF, whereas
ARID1A/B and DPF1/2/3 define BAF. The differential in-
corporation of an array of paralogous subunits further in-
creases the functional diversity of (P)BAF complexes.
The isolated SMARCA2/4 ATPases are capable of remod-
eling in vitro, albeit at a lower level than the whole SWI/
SNF complex (Phelan et al. 1999). The association of the
core subunits SMARCB1, SMARCC1, and SMARCC2
with SMARCA4 suffices to restore untargeted remodeling
activity to the level of the full SWI/SNF complex. It is in-
structive to compare the roles of Drosophila BAP and
PBAP, because they share an identical remodeling core
(Table 1). Functional dissection of fly SWI/SNF revealed
that the subunits comprising the core play key architec-
tural or enzymatic roles, whereas the BAP- and PBAP-spe-
cific subunits determine most of the genomic targeting
and functional selectivity (Moshkin et al. 2012). BAP
and PBAP have shared functions, but also unique effects
on gene expression, development, and cell cycle progres-
sion (Mohrmann et al. 2004; Moshkin et al. 2007, 2012;
Chalkley et al. 2008). Recent comprehensive analyses of
yeast and human SWI/SNF complexes provided detailed
insights into their assembly, architecture, and functional
organization (Dutta et al. 2017;Mashtalir et al. 2018). Col-
lectively, structure–function dissection of the SWI/SNF
remodelers suggests that they could be considered holoen-
zymes, in which different modules provide different func-
tionalities that direct the remodeling activity.
Recently, a third type ofmammalian SWI/SNF complex
was identified (Alpsoy and Dykhuizen 2018; Gatchalian
et al. 2018; Mashtalir et al. 2018; Michel et al. 2018),
named GBAF (glioma tumor suppressor candidate region
gene 1 [GLTSCR1] BAF) or ncBAF (noncanonical BAF).
GBAF/ncBAF comprises BRD9, GLTSCR1/1L, SMAR
CA2/4, ACTL6A/B, Actin, SMARCC1, SMARCD1,
BCL7, and SS18/L1 (Fig. 4A; Table 1). Surprisingly GBAF
lacks the conserved core subunit SMARCB1, which stim-
ulates chromatin remodeling activity and genomic target-
ing of the canonical SWI/SNF complexes (Phelan et al.
1999; Kia et al., 2008; Nakayama et al. 2017; Sen et al.
2017; Wang et al. 2017). The presence of genes with ho-
mology to the GBAF-specific subunits inDrosophila raise
the possibility that GBAF might be evolutionarily con-
served. BRD9 plays a key role in directing GBAF to a spe-
cific set of genomic loci, in part through binding to BRD4
(Gatchalian et al. 2018; Michel et al. 2018). GBAF targets
includes CTCF- and promoter-proximal sites (Michel
et al. 2018), and in embryonic stem cells (ESCs), loci asso-
ciated with naive pluripotency (Gatchalian et al. 2018). In
summary, the SWI/SNF remodelers comprise a wide
range of complexes that perform specialized, rather than
generic functions.
NuRD mediates nucleosome invasion and histone
deacetylation
NuRD complexes bring together ATP-dependent chroma-
tin remodeling and HDAC activities (Fig. 4B; Kolla et al.
2015; Torchy et al. 2015). Unlike SWI/SNF, which is pre-
sent in all eukaryotes examined, NuRD remodelers, are
restricted to metazoans. Mammalian NuRD complexes
harbor one of three chromodomain ATP-dependent heli-
cases (CHD3-5) and one of the histone deacetylases
HDAC1 or HDAC2 (Kloet et al. 2015; Kolla et al. 2015;
Torchy et al. 2015). CHD3-5 are unique amongst the
CHD family in that they possess double PHD fingers in
their N terminus (Fig. 1B). In addition, NuRD complexes
contain one of two scaffolding proteins (GATAD2A/B),
histone chaperones (RBBP4/7), one histone tail- and
DNA-binding protein (MTA1–3), and one of the CpG-
binding proteins (MBD2/3). Notably, MBD2, but not
MBD3, has been proposed to preferentially bindmethylat-
ed CpG residues (Menafra and Stunnenberg 2014). Alter-
natively, DNA methylation has been suggested to be
required for the binding of bothMBD2 andMBD3 (Hainer
et al. 2016). Finally, the small DOC1 (deleted in oral can-
cer 1) protein is an integral subunit of all NuRD complex-
es and plays a role in its recruitment to target loci (Reddy
A
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Figure 4. Composition of mammalian SWI/SNF and NuRD
complexes. (A) Schematic representation of mammalian SWI/
SNF complexes BAF, PBAF, and GBAF. Due to gene duplication
events, several components of each complex are encoded by up
to three paralogous genes in mammals. Alternative names and
orthologous subunits in yeast and Drosophila are in Table 1. (B)
Mammalian NuRD complex. A NuRD-related HDAC module
lacking CHD3-5 and MBD2/3, associated with PWWP2A/B, is
also illustrated. For details and references, see the text.
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et al. 2010; Spruijt et al. 2010; Mohd-Sarip et al. 2017).
NuRD performs pivotal functions during development
and stem cell differentiation (dos Santos et al. 2014).
NuRDs can act as transcriptional corepressors, which
are recruited through sequence-specific transcription fac-
tors to induce robust gene silencing (Kehle et al. 1998;
Reddy et al. 2010; Chudnovsky et al. 2014; Masuda et al.
2016; Liang et al. 2017). However, a global role for NuRDs
in fine-tuning transcription has also been observed, in par-
ticular in ESCs (Günther et al. 2013; Shimbo et al. 2013;
Bornelöv et al. 2018). Genome-wide studies revealed
that CHD4 associates with the majority of promoters
and enhancers in themammalian genome,where it damp-
ens the levels of cognate gene transcription (Whyte et al.
2012; Reynolds et al. 2012a; Günther et al. 2013; Shimbo
et al. 2013; Bornelöv et al. 2018). Binding to the histone
H3.3 variant might help to recruit NuRD to regions of ac-
tive chromatin, where it then fine-tunes the level of tran-
scription (Kraushaar et al. 2018). Temporal analysis of
gene repression induced by the transcription factor Ikaros
revealed that NuRD drives nucleosome invasion, RNAPII
eviction, and reduced activator binding at target loci
(Liang et al. 2017). This required chromatin remodeling
byCHD4 butwas independent of HDAC activity. Histone
deacetylation occurs later and contributes to the mainte-
nance of gene silencing. The use of aMBD3-inducible sys-
tem in ESCs revealed wide association with active
chromatin, and a role for MBD3-NuRD in transcriptional
dampening that mainly involves nucleosome invasion
(Bornelöv et al. 2018). Again, deacetylation of H3K27 fol-
lowed attenuation of transcription, rather than preceding
it. Thus, amodel is emerging in whichNuRD acts broadly
at many enhancers and promoters to dampen and fine-
tune active gene expression (Bornelöv et al. 2018). In sum-
mary, NuRD acts as a global modulator of transcription,
but it can also function as a transcription factor recruited
corepressor. These differentmodes of NuRD actionmight
reflect a difference in the level of local NuRD recruitment
by transcription factors versus a more general affinity of
NuRD for open chromatin.
NuRD refers to a multitude of different protein assem-
blages. Consequently, studies based on a single subunit
may only reflect the function of a particular subset of
NuRD complexes. For example, MBD2-NuRD, rather
than MBD3-NuRD, appears to form repressive chromatin
(Günther et al. 2013; Menafra and Stunnenberg 2014).
Whereas Mbd3 KO mice are early embryonic lethal,
Mbd2 KO mice are viable (Hendrich et al. 2001; Kaji
et al. 2006; Reynolds et al. 2012a). Therefore, caution
must be taken not to generalize observations based on a
particular subunit to all NuRD family complexes. The
NuRDs appear to be more loosely assembled than SWI/
SNF, and separation of remodeling- and HDAC modules
has been reported (Kunert et al. 2009; Zhang et al. 2016,
2018; Link et al. 2018). These submodules may associate
with selective partners that recruit them to distinct geno-
mic loci. For example, a complex comprising the Droso-
phila Mi2 ATPase and the zinc-finger homeobox protein
MEP1 has been identified (Kunert et al. 2009). ANuRD-re-
lated HDACmodule, lacking CHD3-5 andMBD2/3, asso-
ciates with PWWP2A/B, which recognizes the active
chromatin features H2A.Z and H3K36me3 (Fig. 4B). Re-
cruitment of this module by PWWP2A/B to active genes
reduces the level of histone acetylation to decrease tran-
scriptional elongation (Link et al. 2018; Zhang et al.
2018). Thus, some NuRD subunits are also part of alter-
nate complexes that either lack remodeling or HDAC
activity.
Polycomb-repressive complexes (PRCs) in Drosophila
and mammals
Polycomb group (PcG) proteins are a large family of
conserved chromatin regulators that are essential for
maintaining cellular identity in higher eukaryotes
(Schuettengruber et al. 2017). PcG genes were discovered
in Drosophila as repressors of homeotic (Hox) genes
(Kassis et al. 2017; Schuettengruber et al. 2017). The
maintenance of established patterns of Hox and other
developmental gene expression requires the antagonistic
activities of the PcG and Trithorax group (TrxG) pro-
teins. While the PcG proteins maintain repression, the
TrxG proteins contribute to sustaining active gene tran-
scription. The names of many of the PcG genes were in-
spired by the phenotype of extra sex combs appearing on
the second and third pair of legs of male flies, when nor-
mally these bristles only form on the first pair of legs.
This distinctive phenotype is caused by the derepression
Table 1. SWI/SNF class remodeler subunits in yeast, flies, and
humans
A list of subunits of SWI/SNF class remodelers in S. cerevisiae,
Drosophila, and humans. Alternative names are indicated.
Color shading corresponds to conservation across species and
subcomplexes. See the text for details and main references.
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of the sex combs reduced Hox gene and provided a pow-
erful diagnostic for subsequent genetic screens to identi-
fy additional PcG- and TrxG genes (Kassis et al. 2017).
InDrosophila,mostPcGproteins function as part of two
broad classes of multiprotein complexes, named PRC1
and PRC2 (Kassis et al. 2017; Schuettengruber et al.
2017). The core of Drosophila PRC2 is formed by E(z), Su
(z)12, CAF1-p55, and Esc (Fig. 5A). E(z) is a SET domain
containing histone methyltransferase that, as part of
PRC2, trimethylates histone H3K27 (H3K27me3), which
is essential for PcG repression (Pengelly et al. 2013). There
are two main forms of PRC2 in flies, defined by whether
they contain the alternative subunits Pcl (Polycomb-
like) or Jarid2 (Nekrasov et al. 2007; Herz et al. 2012).
The PRC1 class is further subdivided into canonical
(cPRC1) and noncanonical PRC1 (ncPRC1) (Fig. 5B). Dro-
sophila cPRC1 comprises Pc, Psc [or Su(z)2], Ph, and Sce
(also known as dRing), and while Scm associates with
cPRC1, it is considered a substoichometric subunit.
cPRC1 binds PRC2-mediated H3K27me3 via the chromo-
domain of Pc (Cao et al. 2002; Fischle et al. 2003) and
is thought to mediate repression through chromatin
compaction and loop formation (Francis et al. 2004; Entre-
van et al. 2016;Ogiyama et al. 2018). Fly ncPRC1, original-
ly named dRAF (dRing-associated factors), is defined
by a core complex composed of Sce, Psc, and Kdm2 but
lacks Pc and Ph and can include Rybp (Lagarou et al.
2008; Fereres et al. 2014). ncPRC1 couples the removal
of the active H3K36me2 mark with the deposition of
H2AK118ub, whereas cPRC1 lacks appreciable H2Aubiq-
uitylation activity (Lagarou et al. 2008). While the
H2AK118ub mediated by ncPRC1 is required for viability
and helps to promote PRC2mediated H3K27me3, it is not
essential for Hox gene repression (Kalb et al. 2014; Pen-
gelly et al. 2015).
In mammals, PcG proteins perform essential functions
during development, cell differentiation and disease
(Schuettengruber et al. 2017). As in Drosophila, genome-
wide binding studies in mammalian cells confirmed that
PcG proteins directly bind to the gene loci of Hox and oth-
er key developmental regulators (Schuettengruber et al.
2007). Although the key PcG proteins, PRC organization,
and histone modifications are all conserved, the Poly-
comb system has expanded in mammals, compared with
flies (Schuettengruber et al. 2017). In mammals, both
cPRC1 and ncPRC1 are defined by a heterodimeric
RING-PCGF (PcG ring finger) core, which can function
as an E3 ubiquitin ligase to monoubiquitinate H2AK119
(Lys118 in Drosophila) (Wang et al. 2004; McGinty et al.
2014; Blackledge et al. 2015). There are two variants of
the RING subunit in mammals, RING1A and RING1B,
each of which can form a heterodimer with one of six var-
iants of the PCGF subunit PCGF1–6 (Fig. 5B; Gao et al.
2012). cPRC1 contains either PCGF2 (MEL18) or PCGF4
(BMI1) in addition to one chromobox (CBX2, CBX4,
CBX6, CBX7, or CBX8), one sex combs midleg (SCMH1,
SCML1, and SCML2), and one polyhomeotic (PHC1–3)
subunit (Simon and Kingston 2009).
As in flies, the PRC2 complex is responsible for medi-
ating all H3K27me1/2/3 on chromatin (Conway et al.
2015; Højfeldt et al. 2018). The core PRC2 complex is
composed of one of the two histone H3K27 methyltrans-
ferases, Ezh1 or Ezh2, together with Suz12 and Eed,
which are required for histone methytransferase activity
(Margueron and Reinberg 2011). In addition, several ac-
cessory proteins associate with core PRC2, which are
thought to modulate the recruitment and enzymatic ac-
tivity of the complex (Fig. 5A; Laugesen et al. 2019). Dro-
sophila Pcl has three mammalian homologs (Phf1, Mtf2,
and Phf19), while Jarid2 and Aebp2 (Jing in flies) are con-
served as well. Additional interacting proteins include
Epop, Pali1, and Pali2 (Holoch and Margueron 2017; Con-
way et al. 2018). Comprehensive proteomic analyses
showed that PRC2 primarily assembles into two mutual-
ly exclusive combinations, termed PRC2.1 and PRC2.2
(Alekseyenko et al. 2014; Hauri et al. 2016). PRC2.1 is de-
fined as containing one of the three Pcl proteins, while
PRC2.2 is defined as containing Aebp2 and Jarid2 (Mar-
gueron and Reinberg 2011; Holoch and Margueron
2017). There is additional variation within the PRC2.1
subtype, such that one Pcl protein is a constant and defin-
ing feature, while the presence of EPOP and PALI1 are
mutually exclusive (Alekseyenko et al. 2014; Hauri
et al. 2016). Therefore, while PRC2.1 and PRC2.2 are sim-
ilar to Drosophila Pcl-PRC2 and Jarid2-PRC2, respective-
ly, additional accessory proteins of PRC2.1 have emerged
during evolution, providing additional opportunities for
regulation (Fig. 5A).
Mechanisms of recruitment and formation of Polycomb-
repressive domains
The recruitment of PcG proteins has been well-studied in
flies. It is mediated by specific cis-regulatory DNA se-
quences named Polycomb response elements (PREs) (Kas-
sis et al. 2017). PREs are essential for the establishment
and propagation of Polycomb-repressed chromatin (Bustu-
ria et al. 1997; Coleman and Struhl 2017; Laprell et al.
2017). The sequence-specific transcription factor Pho
plays a central role in the recruitment of PRC1 and
PRC2 to PREs (Brown et al. 1998; Frey et al. 2016; Erceg
et al. 2017; Kassis et al. 2017). Pho and PRC1 bind to
PREs cooperatively, generating a nucleosome free region
(Mohd-Sarip et al. 2006, Schuettengruber et al. 2014).
Pho associates with Sfmbt to form PhoRC (Klymenko et
al. 2006). Next, Scm, through binding to Sfmbt, PRC1,
and PRC2, provides a functional link between these three
complexes (Kang et al. 2015; Frey et al. 2016). SAM-
domain mediated polymerization of Scm and Ph might
further contribute to the generation of PcG silenced do-
mains or long-range interactions, possibly directed by
H3K27me3 (Kang et al. 2015; Wani et al. 2016). While
PHO-binding sites are necessary, they are not sufficient
for PRC recruitment, consistent with the essential contri-
butions of additional transcription factors (Kassis et al.
2017; Brown et al. 2018). In summary, PcG recruitment
in flies is achieved through a network of protein–protein
interactions andDNA-binding that tether PRCs to regula-
tory DNA elements. Rather than a universal hierarchical
Chromatin regulation by remodelers and Polycomb
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process, PcG repression involves a mix of cooperative and
redundant mechanisms that differ in different contexts
(Kassis et al. 2017; Brown et al. 2018; De et al. 2019).
In mammals the role of PRC2-mediated H3K27me3 in
directing cPRC1 to target genes via chromodomains with-
in its CBX subunits (themammalian Pc homologs) is well-
defined (Margueron and Reinberg 2011). Indeed, the ma-
jority of H3K27me3 and PRC2-associated genes are
cobound by cPRC1 complexes in multiple mammalian
cell types (Boyer et al. 2006; Bracken et al. 2006). After
binding, cPRC1 is thought to confer gene repression by
chromatin compaction through its CBX and PHC1–3 sub-
units (Isono et al. 2013; Lau et al. 2017). While the role of
H3K27me3 in directing cPRC1 is well-defined in mam-
malian cells, much less is known about the role of
PRC2-mediated H3K27me2 (Conway et al. 2015).
H3K27me2 is present on almost all intergenic euchroma-
tin regions in bothmammals andDrosophila (Ferrari et al.
2014; Conway et al. 2015; Lee et al. 2015) and has been
proposed to form a repressive “genomic blanket” to pre-
vent the misfiring of cell type-specific enhancers of alter-
native lineages (Conway et al. 2015). Thus, the PRC2
complex is believed to contribute to the maintenance of
cellular identity via both H3K27me3 and H3K27me2.
As inDrosophila, ncPRC1 is responsible for the majori-
tyofH2Amonoubiquitination inmammalian cells (Black-
ledge et al. 2014). The ncPRC1 assemblages all lack the
CBX (Pc in flies) and PHC (Ph in flies) proteins (Gao et al.
2012). Instead, they contain one of the paralogs RYBP or
YAF2 that interact directlywithRING1Aor RING1B. An-
other distinctive feature of mammalian ncPRC1 assem-
blages is that they contain any of PCGF1/3/5/6, each of
which associate with specific additional subunits (Fig.
5B). For example, PCGF6-containing ncPRC1 harbors sev-
eral transcription factors, including E2F6, MAX, and
MGA, whereas the PCGF1-containing ncPRC1 includes
the lysine demethylase KDM2B together with BCOR,
SKP1, and the deubiquitylating enzyme USP7 (Fig. 5B).
KDM2B can bind to unmethylated CpG islands via its
CxxC motif and recruits PCGF1-ncPRC1, which can
then deposit H2AK119ub (Fig. 5C; Wu et al., 2013; Black-
ledge et al. 2014). This H2AK119ub modification has
been suggested to contribute to the recruitment of
PRC2.2 via its Jarid2 subunit, which contains a ubiqui-
tin-binding motif (Cooper et al. 2016). Supporting this
model, reduced H2AK119ub in ESCs lacking either
RING1 proteins or combinations of ncPRC1-specific
PCGFs leads to a partial reduction in PRC2 and
H3K27me3 levels on Polycomb target genes (Blackledge
A
B
C
D
Figure 5. Polycomb group protein complexes and chromatin re-
pression. (A) Schematic representation of PRC2.1 and PRC2.2
complexes. Drosophila melanogaster PRC2 components are
shown in the colored ovals, and their mammalian homologs are
also indicated. In mammals, PRC2 has a trimeric enzymatic
core composed of EZH1/2–SUZ12–EED. PRC2.1 contains one
PCL protein and the vertebrate- and eutherian-specific proteins
PALI1/2 and EPOP, respectively. In PRC2.2, these proteins are re-
placed by AEBP2 and JARID2. (B) Schematic representation of
cPRC1 and ncRC1. D. melanogaster PRC1 are indicated in the
colored ovals. The names of their sometimes multiple mammali-
an homologs are also indicated. The enzymatic core of PRC1 is a
RING-PCGF heterodimer, (which is present in cPRC1) and
ncPRC1. In cPRC1, RING-PCGF associates with one of each of
the CBX, PHC, and SCM proteins. In ncPRC1, RING-PCGF asso-
ciates with either a RYBP or YAF2 subunit. (Right panels) The dif-
ferent ncPRC1 complexes are defined by their specific PCGF
subunit, which in turn associate with divergent subsets of inter-
acting proteins. (C )Multipleways of PRC recruitment to chroma-
tin. As detailed in the text, KDM2B binds CpG islands (CGIs),
thus targeting ncPRC1 (1) and H2A ubiquitylation (2). Poly-
comb-like proteins also bind CpG islands (3) and mediate
H3K27 methylation by PRC2.1 (4). (5) H3K27me3 is recognized
by EED, which then allosterically activates PRC2, thus facilitat-
ing the establishment of H3K27me3 domains. (6) The ncPRC1
mark H2Aub is recognized by JARID2, promoting local
H3K27me3 by PRC2.2. (7) H3K27me3, in turn, is bound by
CBX proteins in cPRC1 complexes that mediate chromatin com-
paction. (8) PCGF3/5/6 ncPRC1 complexes harbor sequence-spe-
cific DNA binding proteins that target H2Aub to chromatin.
While, they also target nonclassical PcG sites, theymay also con-
tribute to promoting deposition of H3K27me3 via PRC2.2 bind-
ing to H2Aub. (D) Recruitment of the various PRC complexes
generates a repressive chromatin environment characterized by
H3K27me3, H2Aub, and chromatin compaction mediated by
long-range interactions involving SAM domain-mediated poly-
merization of the CBX2 and PHC1-3 subunits. These PcG si-
lenced domains are sometimes referred to as Polycomb bodies
(red), that are separate in nuclear space from open transcribed
chromatin (green).
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et al. 2014; Fursovaet al. 2019; Scelfo et al. 2019).However,
while the loss of RING1A/B in bothmouse colon and skin
cells in vivo leads to complete loss of H2AK119ub, global
levels of H3K27me3 are maintained (Chiacchiera et al.
2016; Cohen et al. 2018). Therefore, it appears that while
recognition of H2AK119ub by JARID2-PRC2.2 contrib-
utes to local accumulation of H3K27me3 in some con-
texts, it cannot be the sole mechanism. It is likely that
even in the absence of H2A ubiquitylation, Polycomb-
like proteins can still direct PRC2.1 to mediate
H3K27me3. Supporting this, Drosophila embryos engi-
neered to lack all H2AK118ub maintain the repression of
Hox genes and do not exhibit a Polycomb phenotype (Pen-
gelly et al. 2015). Furthermore, the loss of Pcl, but not
Jarid2, leads to Hox gene derepression in Drosophila. Al-
though the mechanisms still need to be worked out in
mammalian cells, Polycomb-like proteinsmay provide al-
ternate means of engagement with chromatin through
binding to H3K36me2/3 and H3K27me3 via their con-
served Tudor domain (Ballaré et al. 2012; Brien et al.
2012, 2015; Cai et al. 2013) or interaction with GC-rich
DNA via their winged helix (WH) domain (Choi et al.
2017; Li et al. 2017; Perino et al. 2018).
In summary, it is clear that there are multiple interde-
pendent interactions between the variousPRCs thatmedi-
ate their association with chromatin in mammalian cells
(Fig. 5C). The ncPRC1 complexes can direct H2AK119ub
to chromatin via either KDM2B binding to CpG islands
or DNA-binding transcription factors. The H2AK119ub
modification is in turn recognized by PRC2.2, which
thendepositsH3K27me3.PRC2.1 is targeted to chromatin
via its Polycomb-like proteins. The combined action of
both PRC2 subtypes results in a genomic profile of
H3K27me3, which is then recognized by cPRC1. The ac-
tivities of cPRC1 mediate long-range interactions and
compact the chromatin via SAM-directed oligomeriza-
tion, generating Polycomb-repressed domains (Fig. 5D).
In conclusion, despite the general conservation of the Pol-
ycomb system inmulticellular eukaryotes, expansion and
subfunctionalization in vertebrates enables diversemech-
anisms of recruitment and fine-tuning of gene expression.
Regulatory interplay between NuRD, Polycomb, and
SWI/SNF
The SWI/SNF, NuRD, and PcG complexes do not func-
tion in isolation, but are part of a regulatory network
that also involves other chromatin regulators and tran-
scription factors. This was first highlighted by genetic
studies in Drosophila that identified suppressors of PcG
mutations, forming the TrxG genes (Kennison and Tam-
kun 1988; Kassis et al. 2017; Schuettengruber et al.
2017). The TrxG genes encode a diverse set of proteins in-
volved in various aspects of chromatin regulation and
transcription (Kassis et al. 2017; Schuettengruber et al.
2017). They include the MLL/COMPASS histone H3K4
methyltransferases (that includes Trx), subunits of the
mediator complex, the cohesin subunit Rad21, the Brd4-
related fs(1)h, the remodelers Brm and Kismet, and the se-
quence-specific DNA-binding proteins Gaga and Zeste.
TrxG genes were identified in two different ways. Some,
including the founding member trx, were identified as ac-
tivators of Hox gene expression. Others, such as Brm,
were discovered in screens for suppressors of Pcmutations
(Kennison and Tamkun 1988; Kassis et al. 2017). Brm en-
codes the fly homolog of yeast Swi2/Snf2 (Table 1; Tam-
kun et al. 1992). The SWI/SNF core subunit Moira (Mor)
and BAP-selective subunit Osawere also identified as sup-
pressors of Pc (Kennison and Tamkun 1988; Collins et al.
1999; Crosby et al. 1999; Kal et al. 2000). Direct tests re-
vealed that the PBAP signature subunits Bap170, Poly-
bromo, and Sayp are also suppressors of Pc (Chalkley
et al. 2008). The transcription factor Zeste belongs to
the TrxG and hasmany binding sites within PREs. A com-
bination of biochemical and in vivo observations showed
that Zestemediates themaintenance of an activated state
through recruitment of (P)BAP (Kal et al. 2000; Déjardin
and Cavalli 2004). Zeste binds to its DNA sites in a chro-
matin template by itself, but (P)BAP is required for tran-
scription activation (Kal et al. 2000). Zeste tethers (P)
BAP via direct binding to the TrxG subunits Mor (core),
Osa (BAP) and Bap170 (PBAP). In conclusion, genetic stud-
ies inDrosophila established that SWI/SNF and Polycomb
act antagonistically in a dosage-dependent manner. Anal-
ysis of the role of SWI/SNF in human cancer revealed the
conservation of this mechanism of gene control. In rhab-
doid tumor cells, the loss of SMARCB1 compromises
SWI/SNF opposition of Polycomb repression (Kia et al.
2008; Wilson et al. 2010). Genome-wide analysis revealed
that SWI/SNF counteracts Polycomb repression of a mul-
titude of genes, in particular at bivalent promoters
(Nakayama et al. 2017; Wang et al. 2017). Artificial re-
cruitment of SWI/SNF leads to a rapid (within minutes),
ATP-dependent eviction of PRCs, which is independent
of RNAPII transcription (Kadoch et al. 2017; Stanton
et al. 2017). These studies suggest that SWI/SNF can re-
move PRCs from the chromatin through a direct mecha-
nism (Fig. 3B). Conversely, in vitro studies showed that
PRC1 can inhibit chromatin remodeling by SWI/SNF
(Francis et al. 2001). Collectively, these studies suggest
that SWI/SNF and Polycomb compete in a dosage-depend-
end manner to generate opposing chromatin states.
NuRD and SWI/SNF also act antagonistically on com-
mon regulatory elements. In ESCs, SWI/SNF, and NuRD
have opposite effects on the nucleosome organization of
shared targets (Yildirim et al. 2011; Hainer et al. 2015).
Likewise, in oral squamous carcinoma cells NuRD and
SWI/SNF compete for binding to genes that encodemaster
regulators of the epithelial-to-mesenchymal transition
(EMT) (Mohd-Sarip et al. 2017). NuRD mediates the
formation of repressive chromatin through nucleosome
invasion, histone deacetylation, and subsequent Poly-
comb recruitment. In contrast, SWI/SNF generates open
chromatin and counteracts Polycomb. These results sug-
gest that transcriptional control involves a dynamic equi-
librium between opposing chromatin modulating
enzymes rather than a static chromatin state. In agree-
mentwith thisnotion, the inductionof repressive chroma-
tin in pre-B cells by the transcription factor Ikaros is
Chromatin regulation by remodelers and Polycomb
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accompanied by the replacement of SWI/SNF by NuRD
(Liang et al. 2017). The Drosophila Ikaros-related tran-
scription factor Hunchback represses theHox genes early
in development through NuRD recruitment (Kehle et al.
1998).After expression ofHunchback ceases later in devel-
opment, gene repression is maintained by the Polycomb
system. These early observations in Drosophila first sug-
gested that NuRDmight create a chromatin environment
that facilitates subsequent Polycomb repression (Fig. 3C).
This notion has been expanded by studies in mice, ESCs,
and human cancer (Morey et al. 2008; Reynolds et al.
2012b; Egan et al. 2013; Sparmann et al. 2013; Mohd-Sarip
et al. 2017). The loss of NuRD-mediated histone deacety-
lation activity in Mbd3 null ESCs correlates with a loss
of PRC2 association on a subset of CHD4 target genes
(Reynolds et al. 2012b). Thus, deacetylation of H3K27
might be a prerequisite for methylation and subsequent
stabilization of PRC2 binding (Fig. 3C). Likewise, the
depletion of CHD5 leads to a loss of H3K27me3 on
CHD5 and PRC2 cobound genes (Egan et al. 2013). The
CHD3–5proteins all contain twoPHDand twochromodo-
mains (Fig. 2A), which have been proposed to act synergis-
tically todetermine their histone-binding specificity (Egan
et al. 2013). The double PHD domains bind to unmodified
H3K4, while the double chromodomains bind to
H3K27me3 in vitro (Egan et al. 2013; Paul et al. 2013).
Thus, PRC2 might also help NuRD recruitment, creating
a positive feedback loop for NuRD and PRC2 targeting to
chromatin. Alternatively, through an indirect process,
transcriptional repression by NuRD might allow the de-
fault binding of PRC2 to CpG islands of silenced genes
(Riising et al. 2014). In conclusion, at least on a subset of
regulatory sites, SWI/SNF and NuRD compete for access
to chromatin and generate opposite chromatin states.
Remodelers and Polycomb in human cancers
Cancer genome sequencing studies revealed that chroma-
tin regulatory proteins are among the most highly mutat-
ed in human cancer (Bailey et al. 2018; Gröbner et al. 2018;
Ma et al. 2018). This indicates that disruptions in the bio-
chemical mechanisms that control chromatin dynamics
may play a significant role in the development of many
cancers. Approximately 30%of newly identified potential
cancer “driver” mutations occur in genes that encode
chromatin regulators. Within this functional class, genes
encoding selective SWI/SNF subunits are remarkably
prone to mutations (Kadoch et al. 2013; Shain and Pollack
2013;Masliah-Planchon et al. 2015). More than 20% of all
cancers have mutations in SWI/SNF members, making
these complexes the most frequently mutated remodelers
in cancer (Fig. 6). Genes encoding different SWI/SNF sub-
units aremutated at high frequencies in specific, nonover-
lapping malignancies, indicating that they might have
nonredundant tumor-suppressive functions. In addition
to clear truncating, loss-of-function or loss-of-expression
mutations, a substantial portion of mutations in SWI/
SNF genes are substitution mutations that are distributed
rather evenly across the coding sequence at relatively low
frequency. Although these substitutions might affect pro-
tein stability, their potential role as drivers of cancer re-
mains to be determined. Genes encoding members of
the PRC2 complex are also mutated at elevated frequen-
cies in particular cancers (Fig. 6). Intriguingly, thesemuta-
tions can lead to either increased or decreased levels of
H3K27me3, which varies depending on tissue or disease
subtype (Conway et al. 2015). Below, we discuss instruc-
tive examples of how altered remodeler or Polycomb func-
tion promotes the development of cancer, highlighting
our burgeoning understanding of the underlying molecu-
lar mechanisms. We start by reviewing rhabdoid tumors
and synovial sarcoma in detail, because they are the
best-understood cancers that are caused by aberant SWI/
SNF function. Next, we review examples of cancers
Figure 6. Chromatin remodelling complexes are frequently mu-
tated in cancer. Mutations in different SWI/SNF subunits associ-
atewith different types of cancer. The percentage of mutations in
specific types of cancer are indicated. Adult cancers are shown in
blue, pediatric cancers in red. Cancer-associated mutations in
NuRD do occur, but are less frequent than in SWI/SNF. The en-
zymatic core of PRC2 is subject to both activating (in diffuse large
B-cell and follicular lymphoma) and inactivating (in T-cell acute
lymphoblastic leukemia and malignant peripheral nerve sheath
tumors) mutations. The primary substrate of the PRC2 complex,
H3K27, is also the target of an oncogenic mutation in the major-
ity of paediatric diffuse intrinsic pontine glioma tumours. Muta-
tion rates, which are indicated for each disease, are taken from the
Cancer Genome Atlas (TCGA) pan-cancer atlas (Gao et al. 2018)
for adult cancers and for pediatric diseases from recent pan-paedi-
atric cancer genmics studies (Gröbner et al. 2018; Ma et al. 2018).
Cancer studies are indicted by their TCGA abbreviations. For de-
tails and references, see the text.
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with additional SWI/SNF, NuRD, or PRC2 alterations. Fi-
nally, we discuss how perturbing the balance of SWI/SNF,
NURD, and Polycomb activities may affect transcription-
al programs and cell identity to promote oncogenesis.
SMARCB1 in rhabdoid tumors
The first evidence for a causative role for mSWI/SNF de-
fects in oncogenesis came from studies on rhabdoid tu-
mors (RTs) (Versteege et al. 1998; Biegel et al. 1999). RTs
are deadly pediatric cancers of the central nervous system
(CNS), kidney and soft tissues, which typically occur in
children <2 yr of age (Masliah-Planchon et al. 2015; Sredni
and Tomita 2015; Frühwald et al. 2016). These cancers are
also referred to as atypical teratoid RTs (ATRT) when lo-
cated in the CNS, or extracranial malignant RTs (ecMRT)
when located elsewhere in the body. The vast majority of
RT cases (∼99%) have biallelic loss of the SMARCB1 gene
(Fig. 6). A small minority of RTs are associated with
mutations in SMARCA4 rather than SMARCB1 (Schnep-
penheim et al. 2010; Hasselblatt et al. 2014). Families har-
boring germline mutations in SMARCB1 or SMARCA4
are predisposed to the development of RT, referred to as
RT predisposition syndrome (RTPS) (Sévenet et al. 1999;
Sredni and Tomita 2015). The genomes of RTs display
no substantial genomic instability and have very lowmu-
tational burden, with loss of SMARCB1 as the sole recur-
ring event (Lee et al. 2012; Lawrence et al. 2013; Chun
et al. 2016; Torchia et al. 2016; Gröbner et al. 2018; Pinto
et al. 2018). Thus, inactivation of SMARCB1 appears to be
sufficient to drive oncogenesis in the absence of collabo-
rating genetic abnormalities. While biallelic loss of
Smarcb1 leads to early lethality during mouse develop-
ment, haplo-insuffient mice are prone to develop tumors
that resemble human RTs, showing loss of heterozygosity
that is typical for a tumor suppressor (Klochendler-Yeivin
et al. 2000; Roberts et al. 2000; Guidi et al. 2001). Revers-
ible conditional inactivation of Smarcb1 in mice revealed
that, while it is essential for the survival of most normal
cells, it also causes highly penetrant and aggressive can-
cers (Roberts et al. 2002). The vast majority of these tu-
mors were T-cell lymphoma with only rare cancers that
resembled RTs. Nonetheless, these mouse experiments
established that loss of Smarcb1 causes cancer in mouse
models. Inactivation of Smarcb1 at different stages of
mouse development leads to dramatically different out-
comes (Han et al. 2016). While full Smarcb1 deletion dur-
ing early development is lethal, its partial inactivation at
embryonic day 6–10 (E6–E10) results in highly penetrant
rapid onset CNS tumors that closely resemble human
RT. In agreement with earlier observations, loss of
Smarcb1 in adult mice causes lymphomas instead of
RT. The predisposition to the development of childhood
RTs is not fully penetrant among RTPS families with
germline mutations in SMARCB1, and its development
in adults from these families is extremely rare (Taylor
et al. 2000; Janson et al. 2006; Ammerlaan et al. 2008;
Sredni and Tomita 2015). However, these adults frequent-
ly develop multiple schwannomas and benign tumors in-
volving cranial and peripheral nerves. Thus, both patient
data and mouse studies provide strong evidence for devel-
opmental stage as themajor factor determining the conse-
quences of SMARCB1 inactivation.
While several studies have addressed the alterations in
gene expression in RT; interpretations have been compli-
cated by the substantial heterogeneity among tumors
(Chun et al. 2016; Torchia et al. 2016; Richer et al. 2017;
Pinto et al. 2018). An embryonic gene expression signa-
ture distinguishes RT from other cancers that are
SMARCB1-deficient (Richer et al. 2017). Consistent
with SWI/SNF’s role as a member of the TrxG, dysregula-
tion of Hox genes is frequently observed in RTs (Chun
et al. 2016; Torchia et al. 2016; Richer et al. 2017; Pinto
et al. 2018). Although more research is required to deter-
mine the significance of specific transcriptional perturba-
tions in RT, the retention of an embryonic signature is
likely a key aspect in the development of these tumours.
Furthermore, loss of SMARCB1 can affect cell cycle con-
trol in multiple ways. For example, inactivation of
SMARCB1 has been implicated in silencing of CDKN2A,
encoding the pivotal tumor suppressor p16INK4a, in cell
lines, mouse models, and human tumors (Betz et al.
2002; Oruetxebarria et al. 2004; Kia et al. 2008; Wilson
et al. 2010; Venneti et al. 2011).CDKN2A is awell-charac-
terized target of PcG proteins, linked to their ability to
suppress cellular senescence (Jacobs et al. 1999; Bracken
et al. 2007). Therefore, a key consequence of the loss of
SMARCB1 in RTs is that it compromises the ability of
the SWI/SNF complex to counteract Polycomb-mediated
repression ofCDKN2A (Kia et al. 2008;Wilson et al. 2010).
The loss of SMARCB1 does not substantially debilitate
the structural integrity of BAF or PBAF (Nakayama et al.
2017;Mashtalir et al. 2018), but does compromise their re-
cruitment to key target sites (Kia et al. 2008; Tolstorukov
et al. 2013; Nakayama et al. 2017; Wang et al. 2017). In ad-
dition, SMARCB1/Snf5 binds the SMARCA4/Snf2 cata-
lytic subunit and stimulates nucleosome remodeling by
mammalian and yeast SWI/SNF (Phelan et al. 1999; Sen
et al. 2017). Recent genome-wide studies demonstrated
that SMARCB1 is important for recruitment of SWI/
SNF to developmental enhancers (Nakayama et al. 2017;
Wang et al. 2017; Erkek et al. 2019). Loss of SWI/SNF bind-
ing at these sites is associated with PRC2 binding and re-
pression of cognate developmental gene promoters,
indicating that the SWI/SNF–Polycomb antagonism ob-
served at theCDKN2A locus occurs genomewide. Impor-
tantly, EZH2 is essential for tumor formation after
conditional loss of SMARCB1 in mice (Wilson et al.
2010), and treatment with small molecule EZH2 inhibi-
tors led to regression of RT in a xenograft model (Knutson
et al. 2013). Thus, an important aspect of RT development
is the loss of SWI/SNF antagonism to PcG repression.
While the loss of SMARCB1 compromises both BAF and
PBAF, it does not affect GBAF that lacks this subunit
(Alpsoy and Dykhuizen 2018; Gatchalian et al. 2018;
Mashtalir et al. 2018; Michel et al. 2018). Therefore, it is
of interest that chemical probes that target the GBAF sub-
unit BRD9 inhibit proliferation of RT cell lines (Krämer
et al. 2017; Michel et al. 2018). Collectively, these
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observations suggest that RTsmight be especially vulner-
able to combined targeting of BRD9 and EZH2. In addi-
tion, due to their stable genomes, the canonical tumor
suppressor pathways remained intact in RT, and might
be exploited as well. In conclusion, the detailed dissection
of gene control in RT starts to provide leads for potential
therapeutic intervention.
SS18-SSX fusions in synovial sarcoma
Synovial sarcoma is an aggressive, poorly differentiated
malignancy that canoccur in patients of all ages, but is par-
ticularly common in children and young adults with a
peak incidence between 20 and 30 yr of age. The hallmark
genetic abnormality is a chromosomal translocation in-
volving chromosomes X and 18, t(X;18). This rearrange-
ment fuses the N terminus of the BAF and GBAF subunit
SS18 (also known as SYT) to theC terminus of one of three
related proteins, SSX1, SSX2, or SSX4 (Clark et al. 1994; de
Leeuw et al. 1995; Skytting et al. 1999). Like RTs [other
than t(X:18)], synovial sarcoma tumors contain few, if
any, genetic abnormalities (Barretina et al. 2010; Abes-
house et al. 2017). This suggests that the SS18-SSX fusion
protein is the primary driver of disease development. In-
deed, conditional expression of SS18-SSX leads to the de-
velopment of a synovial sarcoma-like disease in mice
(Haldar et al. 2007). Similar to results observed in
Smarcb1-deficient mouse models, both cellular context
and developmental timing are critical for the ability of
SS18-SSX to induce tumors. For example, while the ex-
pression of SS18-SSX in mature muscle lineages causes
myopathy without tumorigenesis, when expressed in im-
maturemuscleprogenitor cells, adultmicedevelop aggres-
sive tumors with 100% penetrance (Haldar et al. 2007).
SS18-SSXdominantly assembles into SWI/SNF, causing
the eviction and proteasomal degradation of both thewild-
type SS18 and SMARCB1 (Kadoch and Crabtree 2013).
Therefore, in both RT and synovial sarcoma, SMARCB1
is lacking from BAF (but not from PBAF). However, the as-
sembly of SS18-SSX into BAF, and not SMARCB1 loss, ap-
pears to be the primary pathogenic alteration (McBride
et al. 2018). SS18-SSX does not associate with PBAF, but
it assembles into both BAF and GBAF (Brien et al. 2018;
McBride et al. 2018). Given their compositional differenc-
es, it is likely that incorporation of SS18-SSX has unique
functional effects as part of BAFversusGBAF.Thesediffer-
ences need to be explored given the recent demonstration
that synovial sarcoma cells are exquisitely dependent on
GBAF function (Brien et al. 2018; Michel et al. 2018).
Depletion of SS18-SSX correlates with increased PRC2
mediated H3K27me3 and repression of many SS18-SSX
target genes (Banito et al. 2018; McBride et al. 2018).
SS18-SSX containing BAF andGBAF appear to bemore po-
tent antagonists of Polycomb function than their wild-
type counterparts (Kadoch and Crabtree 2013). This sug-
gests that SS18-SSX containing complexes may act domi-
nantly to aberrantly activate Polycomb target genes.
Consistent with this notion, SS18-SSX activates the ex-
pression of many developmental regulators (Banito et al.
2018; McBride et al. 2018). Moreover, cells expressing
SS18-SSXappear to be blocked in their capacity to differen-
tiate (Haldar et al. 2007). Depletion of SS18-SSX triggers
downregulation of developmental gene expression signa-
tures and differentiation toward a mesenchymal cell fate
(Banito et al. 2018; Brien et al. 2018). It has also been sug-
gested that SS18-SSX associates with KDM2B, whichmay
lead to its mis-direction to KDM2B-bound loci (Banito
et al. 2018). Collectively, these results suggest that SS18-
SSX containing BAF and GBAF oppose Polycomb mediat-
ed repression of a primitive development transcriptional
program, causing a block to cellular differentiation.
Mutations of SWI/SNF genes in multiple other cancer
types
Studies on RT and synovial sarcomas established that de-
fects in SWI/SNF subunits SMARCB1 and SS18 cause can-
cer. Sequencing studies revealed that the genes encoding
additional SWI/SNF subunits are frequently mutated in
awide array of other cancer types (Fig. 6). Here, we restrict
our discussion to a selection of SWI/SNF subunits for
which functional studies are beginning to provide mecha-
nistic insights. The BAF-specific ARID1A gene is the
most commonly mutated SWI/SNF component in cancer
(Fig. 6). Its function is primarily lost due to truncatingmu-
tations as has been reported inmultiple cancers, including
bladder cancer (Gui et al. 2011), uterine endometrial carci-
noma (Kandoth et al. 2013), and neuroblastoma (Sausen
et al. 2013). Moreover, recent pan-cancer analyses of al-
most 10,000 adult and 1600 paediatric cancers further
demonstrate the significance of ARID1A mutations in
multiple malignancies (Bailey et al. 2018; Gröbner et al.
2018; Ma et al. 2018). While our mechanistic insights on
the effects of ARID1A loss are still limited, recent studies
suggested that impaired enhancer function might play a
central role. In a mouse model of colon cancer, based on
the conditional deletion of Arid1a, loss of ARID1A corre-
lated with reduced binding of SWI/SNF at enhancers and
reduced expression of cognate genes (Mathur et al.
2017). Another study established that ARID1A loss leads
to reduced chromatin accessibility at enhancers, imped-
ing transcription factor binding (Kelso et al. 2017). Consis-
tent with the observed reductions in gene expression and
chromatin accessibility, many of these enhancers had re-
duced levels of H3K27ac (Kelso et al. 2017; Mathur et al.
2017). Furthermore, the deletion of Arid1a in a mouse
model of hepatocellular cancer also leads to a reduction
in chromatin accessibility and associated gene expression
(Sun et al. 2017). Truncating mutations of ARID1A abro-
gate its ability to associate with the core of the SWI/SNF
complex (Mashtalir et al. 2018). Thus, like its Drosophila
homolog Osa (Moshkin et al. 2012), loss of ARID1a im-
pairs BAF recruitment to chromatin. Given the reductions
in both chromatin accessibility and H3K27Ac at enhanc-
ers following loss of ARID1a, it is tempting to speculate
that the absence of BAF allows NuRD to promote repres-
sive chromatin at these loci. This could contribute to an
impaired ability of these cancer cells to activate key genes
Bracken et al.
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required for differentiation. Finally, oncogene-induced
senescence and activation of p53 in hepatocellular carci-
noma cells depends onARID1B/BAF (Tordella et al. 2016).
PBRM1 loss-of-function genetic alterations are present
in∼40%of kidney renal clear cell carcinoma (KIRC),mak-
ing it second to the VHL tumor suppressor in terms of
frequency (Fig. 6; Varela et al. 2011). Gene expression anal-
ysis revealed substantial changes due to loss of PBAF
function in these cells, which correlates with responsive-
ness to immune checkpoint therapy (Miao et al. 2018). In
an independent screen to identify barriers to killing of can-
cer cells by cytotoxic T cells, inactivation of Pbrm1, Arid2
andBrd7was found tomediate resistance (Pan et al., 2018).
Both studies suggest that PBAF control of interferon-stim-
ulated gene expression promotes immune resistance. Loss
of PBAF function increased tumor cell secretion of chemo-
kines that recruit effector T cells. Thus, targeting
PBAFmight sensitize cancer cells to immunotherapy. Par-
adoxically, in clear cell renal cell carcinoma, loss of PBAF
functionmight promote both tumorigenicity and suscept-
ibility to antitumor immunity.
SMARCA4 is the most commonly mutated Snf2-like
ATPase in cancer, including several adult and pediatric
malignancies (Fig. 6; Bailey et al. 2018; Gao et al. 2018;
Gröbner et al. 2018; Hodges et al. 2018). Similar to
ARID1A, many SMARCA4 mutations are predicted to
inactivate, suggesting that it functions as a tumor sup-
pressor. A portion of the cancer-associated SMARCA4
mutations occur within the ATPase domain (Hodges
et al. 2018). Introduction of these SMARCA4 ATPasemu-
tations into mouse ESCs leads to a loss of chromatin ac-
cessibility and H3K27Ac at enhancers, accompanied by
transcriptional down-regulation, and accumulation of
Polycomb and H3K27me3 at the promoters of associated
genes (Stanton et al. 2017; Hodges et al. 2018). However,
as observed for SMARCB1-deficient RT cells, increased
Polycomb activity occurs specifically at gene promoters
and not at enhancers. These observations indicate that
loss of SWI/SNF function in cancer leads to alterations
in enhancer landscapes. We speculate that this might be
due to increased NuRD activity at these sites. The re-
duced activity of SWI/SNF-dependent enhancers corre-
lates with an increased activity of Polycomb at the
associated gene promoters, and attenuated transcription.
These effects appear to alter the developmental potential
of SWI/SNFmutant cells, making them linger in an undif-
ferentiated (or incompletely differentiated) state. A recent
analysis of somatic histonemutations in cancer revealed a
substantial number of alterations in the globular domain
that have been implicated in remodeler function (Nacev
et al., 2019). These include mutations homologous to
yeastmutants that alleviate the need for SWI/SNF, and al-
terations in the acidic patch (Fig. 3C) that are predicted to
impair remodeling by ISWI.
The complex roles of NuRD in human cancer
In addition to its well-established roles in cell differentia-
tion programs, disruption of NuRD function has also been
implicated in oncogenesis. However, cancer-associated
mutations in NuRD subunits occur less frequently than
in SWI/SNF components (Kadoch et al. 2013; Bailey
et al. 2018; http://www.cbioportal.org). The gene encod-
ing the CHD5 member of NuRD is a tumor suppressor
that is frequently deleted in high-risk neuroblastoma
and glioma (Bagchi et al. 2007). It is expressed in normal
neuronal tissues and in low-risk neuroblastomas, but its
levels are reduced in tumors from high-risk neuroblasto-
ma patients (Fujita et al. 2008; Garcia et al. 2010; Egan
et al. 2013). CHD5 is required for terminal neuronal differ-
entiation and has a dual role in facilitating the activation
of neuronal genes, as well as the repression of a cohort of
Polycomb target genes (Egan et al. 2013). Therefore, its
loss in neuroblastoma has been proposed to impede the
ability of neural cells to undergo terminal differentiation.
The role of CHD4 in human cancer is more complicated.
In some cancers, CHD4 is mutated with increased fre-
quency, but compelling evidence that these are drivermu-
tations remains lacking. Moroever, CHD4 has also been
linked with pro-oncogenic functions. The recruitment of
CHD4-NuRD by the DNA-binding transcription factor
ZFHX4 is crucial for themaintenance of therapy-resistant
tumor-initiating cells in glioblastoma (Chudnovsky et al.
2014). CHD4 is required for the maintenance of MLL-AF9
rearranged acute myeloid leukemia cells, but not for
growth of normal hematopoietic cells (Heshmati et al.
2018). Conversely, MBD3-CHD4-NuRD prevents tumori-
genesis by constraining a B-cell transcriptional program
through restriction of lineage-specific enhancers and
promoters (Loughran et al. 2017). This process involves
opposing activities of NuRD and SWI/SNF, again empha-
sizing the importance of chromatin balance in develop-
mental transcription control. The DOC1 subunit of
NuRD is lost in themajority of oral cancers and correlates
with tumor invasion and adverse outcomes (Shintani
et al. 2001; Mohd-Sarip et al. 2017). The loss of DOC1 af-
fects recruitment of NuRD to a selection of genes that
control proliferation and EMT (Mohd-Sarip et al. 2017).
At these loci, NuRD and SWI/SNF compete for binding
and generate opposite chromatin states. SWI/SNF drives
formation of open chromatin and counters Polycomb
binding. In contrast, NuRD mediates nucleosome inva-
sion, histone deacetylation, recruitment of Polycomb
and KDM1A, and transcriptional repression. Although
not as well explored as the connection between SWI/
SNF and cancer, these studies indicate that alterations
in NuRD integrity can contribute to oncogenesis. Muta-
tions in or deregulation of NuRD can disturb the balance
with SWI/SNF, leading to the corruption of developmen-
tal programs and proliferation control. As for SWI/SNF,
subunit-dependent gene selectivity is likely to explain
the association with specific types of cancer.
Deregulation of Polycomb function in cancer
Initial links between deregulation of Polycomb function
and cancer were related to their overexpression rather
than driver mutations (Pasini and Di Croce, 2016).
Chromatin regulation by remodelers and Polycomb
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However, there is little evidence of driver mutations in
genes encoding subunits of cPRC1 in human cancer. So,
while overexpression of PRC1 components such as
PCGF4/BMI1 might promote oncogenesis, it might also
be a consequence of the proportion proliferating or stem
like cells in the tumor, rather than a cause. This limited
evidence of cancer driver mutations in genes encoding
cPRC1 subunits might be related to the high level of re-
dundancy among cPRC1 subunits, which would limit
the impact of mutations. However, somatic mutations
in the ncPRC1 subunit BCOR have been identified in
AML and myelodysplastic syndrome, and mouse studies
support a tumor suppressor function in leukemia
(Damm et al. 2013; Tanaka et al. 2017; Kelly et al. 2019).
Bcor has a key function in the regulation of the hemato-
poietic stem cell transcription network and its inactiva-
tion drives expansion of myeloid progenitor cells and
cooperates with oncogenic Kras to drive the development
of leukemia (Kelly et al. 2019). Thus, while the roles of
some PRC1 components in cancer seems mostly related
to their requirement for stem cell survival, BCOR appears
to be a bona-fide tumor suppressor.
Multiple cancer genome sequencing studies have re-
vealed that the function of PRC2 is disrupted on a genetic
level in a wide array of cancers, leading to both loss and
gain of activity (Conway et al. 2015). Prior to these studies,
EZH2 was reported to be highly expressed in multiple can-
cers as a result of being an E2F-regulated gene, downstream
from the pRB pathway (Bracken et al. 2003). However, ele-
vatedEZH2expression is not considered to lead to deregula-
tion of H3K27 methylations, because the stoichiometry of
the core PRC2 complex would require correspondingly
high levels of the EED and SUZ12 subunits (Wassef et al.
2015). In 2010, recurrent heterozygous mutations of the
EZH2 catalytic SET domain in 22% of Diffuse large B-cell
lymphomas (DLBCLs) and 10% of follicular lymphomas
(FLs) were reported for the first time (Fig. 6; Morin et al.
2010). These mutations were originally thought to induce
loss-of-functioneffectsonEZH2enzymaticactivity;howev-
er, additionalworkdemonstrated that themutantEZH2has
altered substrate preferences (Sneeringer et al. 2010). The
preferred activity of wild-type EZH2 is the conversion of
H3K27me0 to me1 and H3K27me1 to H3K27me2, while
the enzyme is relatively inefficient at the final conversion
step to H3K27me3. Owing to changes in substrate-binding
modality, lymphoma associated EZH2 SET domain mu-
tants have an enhanced ability to convert H3K27me2 to
me3.As a result, these“change-of-function”EZH2mutants
cooperate with the wild-type enzyme, pushing the kinetics
of PRC2 activity toward increased H3K27me3 production.
This leads to aberrantly high global levels of H3K27me3,
with concomitant reductions of H3K27me2 levels in
EZH2 mutant lymphoma cells. Importantly, in a mouse
model, conditional expression of this “change-of-function”
EZH2 mutant in B-cell lineages replicates these H3K27
methylation changes and, while augmented by overexpres-
sion of BCL2 or loss of p53, is sufficient to causemalignancy
(Béguelin et al. 2013; Souroullas et al. 2016).
Our understanding of the molecular mechanisms un-
derlying oncogenesis in these EZH2 mutant contexts is
still limited. ChIP-seq (chromatin immunoprecipitation
[ChIP] combined with high-throughput sequencing) ex-
periments have suggested that increased levels of
H3K27me3 mark the promoter regions of genes required
for cell cycle exit and terminal B-cell differentiation
(Béguelin et al. 2013; Souroullas et al. 2016). This corre-
lates with reduced expression of many of these genes, sug-
gesting that mutant EZH2 impedes the differentiation
potential of immature B-cells. Moreover, cPRC1 appears
to maintain the repression of these genes, which may be
linked to recruitment of the CBX8 containing cPRC1 via
binding to H3K27me3 at these sites (Béguelin et al.
2016). To date, the consequences of reduced H3K27me2
levels in these cells and its functional relationship with
H3K27me3 have yet to be examined. This might be im-
portant given that H3K27me2 is known to mark up to
70% of all histone H3 in normal cells (Ferrari et al.
2014). Moreover, H3K27me2 has been suggested to per-
form repressive functions at intergenic sites that are likely
altered in EZH2 mutant lymphoma cells (Ferrari et al.
2014; Conway et al. 2015).
In contrast to lymphomas, the genes encoding core
PRC2 subunits are tumor suppressors in other cancer
types. For example, in paediatric T-cell acute lymphoblas-
tic leukemias (T-ALLs) and malignant peripheral nerve
sheath tumors (MPNSTs) the EZH2, EED, and SUZ12
genes are subject to deletions or inactivating mutations
(Ntziachristos et al. 2012; Zhang et al. 2012; Lee et al.
2014). These loss-of-function alleles are associated with
reductions in the global levels of both H3K27me2 and
H3K27me3. Functional studies showed that the loss of
PRC2 activity in T-ALL andMPNST leads to aberrant ac-
tivation of some PRC2 target genes (Ntziachristos et al.
2012; Lee et al. 2014). It is likely that the loss of PRC2-me-
diated H3K27me3 at these genes leads to increased activ-
ity of SWI/SNF chromatin remodellers. The function of
PRC2 is also deregulated in pediatric diffuse intrinsic pon-
tine gliomas (DIPGs), a highly aggressive pediatric brain-
stem tumor (Mohammad and Helin 2017). The discovery
that up to 80% of DIPG have mutations in two genes en-
coding histone H3F3A (H3.3) or HIST3H1B (H3.1) led to
the finding of global reductions in H3K27me2 and
H3K27me3 in these cells (Conwayet al. 2015). Subsequent
work has suggested that H3K27M can act as a dominant-
negative mutation that, at least partially, inhibits PRC2
(Mohammad and Helin 2017).
Taken together, it is clear that the function of PRC2 is
deregulated in several types of cancer, accompanied by
changes in the global levels and genomic distributions of
H3K27me2 and H3K27me3. While it remains unclear
how these epigenomic changes contribute to the develop-
ment of cancer, it is likely that they confer context-depen-
dent blocks to cellular differentiation and increased
vulnerability to aberrant cancer signaling pathways.
Therapeutic opportunities: restoring or tipping the
chromatin balance
Normal gene expression control depends on the equilibri-
um between SWI/SNF opposed by NuRD and Polycomb
Bracken et al.
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(Fig. 7A). As discussed in this review,many cancers have a
disturbance of this chromatin balance. This common fea-
ture might be exploited therapeutically. For example, in
the context of loss of SWI/SNF function, unrestrained Pol-
ycomb activity appears to mediate aberrant repression of
transcriptional programs related to cellular differentiation
and tumor suppression. Consequently, targeting PRC2
function in SWI/SNF mutant cancers may reverse the on-
cogenic chromatin changes that underlie disease develop-
ment. Consistent with this, codeletion of Ezh2 and Snf5 is
not compatible with cancer development in mice (Wilson
et al. 2010). The recent development of small-molecule
EZH2methyltransferase inhibitors has provided an oppor-
tunity to examine the clinical utility of PRC2 inhibition
in multiple cancers, including those carrying inactivating
mutations in genes encoding SWI/SNF subunits (McCabe
et al. 2012; Knutson et al. 2013; Campbell et al. 2015). As a
proof of concept, SMARCB1-deficient RT cells are more
sensitive to treatment with EZH2 inhibitors than wild-
type cells (Knutson et al. 2013). Moreover, EZH2 inhibi-
tion blocks the progression of SMARCB1 mutant cancers
in vivo, which has motivated the establishment of ongo-
ing clinical trials with EZH2 inhibitors in RTs. Early re-
sults have reported clinical responses in a subset of
SMARCB1 negative patients (Italiano et al. 2018). EZH2
inhibitor treatment of non-small cell lung cancer cells
bearing SMARCA4 mutations sensitizes these cells to
chemotherapy, an effect that is not apparent in
SMARCA4 wild-type cells (Fillmore et al. 2015). Further-
more, Arid1a mutant, but not wild-type ovarian cancer
cell lines are also sensitive to reduction of EZH2 (Bitler
et al. 2015; Kim et al. 2015). These findings indicate that
targeting PRC2 activity in SWI/SNF mutant cancers
may provide an effective means to treat this large cohort
of patients. Finally, targeting HDAC activity, particularly
HDAC2, blocks the progression ofArid1amutant ovarian
cancer cells (Fukumoto et al. 2018). Thus, NuRD com-
plexes, harboring HDAC1/2, may also be relevant in
SWI/SNF mutant cancers. However, the general efficacy
of HDAC inhibitors remains to be systematically exam-
ined in SWI/SNF mutant contexts.
Accumulating evidence indicates that the SWI/SNF
complexes themselvesmaybe an effective therapeutic tar-
get in SWI/SNFmutant cancers. For example, GBAF is es-
sential for the continued growth and survival of synovial
sarcoma cells (Brien et al. 2018; Michel et al. 2018). The
selective targeting of the GBAF subunit BRD9 in a mouse
model of synovial sarcoma effectively blocked tumor pro-
gression, supporting the therapeutic promise of this ap-
proach. Synthetic lethality is another potential strategy
for cancers with loss-of-function mutations in genes en-
coding SWI/SNF subunits (Helming et al. 2014; Hohmann
and Vakoc 2014). Typically, the residual SWI/SNF com-
plexes are essential in these cancer cells, whichmay be ex-
ploited therapeutically (Fig. 7B). For example, SMARCB1
deficient cells require residual SWI/SNF function, because
concomitant loss of SMARCB1 and SMARCA4 blocks
tumor development (Wang et al. 2009). Moreover,
SMARCB1mutantRTcells also dependonBRD9 function
(Krämer et al. 2017; Michel et al. 2018). ARID1A mutant
cancer cells often require the function of its paralog
ARID1B (Helming et al. 2014; Kelso et al. 2017;McDonald
et al. 2017). Likewise, SMARCA4mutant lung cancer cells
depend on SMARCA2 for their continued growth and sur-
vival (Wilson et al. 2014;McDonald et al. 2017). Thus, tar-
geting paralog function in these settings may provide an
effective therapeutic option (Fig. 7B). Recent drug develop-
ment efforts are beginning to uncover molecules that spe-
cifically target SWI/SNF subunits such asARID1A, BRD7,
B
A
Figure 7. Therapeutic opportunities. (A)Maintaining chromatin
equilibrium. Physiological gene expression depends on the ba-
lanced interplay between SWI/SNF, NuRD, and Polycomb. A dis-
turbance in this chromatin equilibrium—for example, due to loss
of one of the SWI/SNF subunits—can promote oncogenesis due to
misexpression of genes that regulate cell proliferation, cell differ-
entiation, EMT, cellular senescence, or apoptosis. A therapeutic
strategy might involve restoring the chromatin balance by com-
pensating for loss of SWI/SNF function by inhibition of PRC2
or NuRD. Conversely, loss of Polycomb function might be com-
pensated for by inhibition of SWI/SNF. (B) Tipping the chromatin
balance. Synthetic lethality provides another potential therapeu-
tic strategy for cancers with loss-of-function mutations in SWI/
SNF. The residual SWI/SNF complexes are often essential for
the viability of these tumor cells, and therefore present attractive
therapeutic targets. For example, SMARCB1 mutant RT cells
depend on BRD9 function. Alternatively, loss of ARID1A might
create a crucial requirement for PBAF or GBAF. The loss of one
subunit (e.g., SMARCA4 in lung cancer cells) can also create a
crucial dependency on its paralog, SMARCA2. Consequently, tar-
geting paralog function in these settings may provide an effective
therapeutic option. For details and references, see the text.
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and BRD9, which will allow this idea to be tested (Hoh-
mann et al. 2016; Theodoulou et al. 2016; Remillard
et al. 2017; Brien et al. 2018; Marian et al. 2018).
The mutation of EZH2 in B-cell lymphomas motivated
the development of small-molecule inhibitors that act as
SAM-competitive binders of the SET domain and exhibit
high selectivity for EZH1/2 (Helin and Dhanak 2013;
Kim and Roberts 2016). These compounds are capable of
reducing global levels of H3K27me1/2/3 in cells, regard-
less of their EZH2 mutational status. Nevertheless,
EZH2 “change-of-function” mutant cells are particularly
sensitive to these drugs.Thismotivated the establishment
of clinical trials to examine their effects in lymphoma pa-
tients (Brien et al. 2016; Kim andRoberts 2016). Recent re-
porting on these ongoing clinical studies indicated
significant responses in EZH2 mutant patients, with as
many as 92% of EZH2-mutant follicular lymphoma pa-
tients responding to treatment (Italiano et al. 2018). Func-
tional studies indicated that EZH2 inhibition leads to
reductions in globalH3K27me3 levels,which is associated
with up-regulation of PRC2 target genes (McCabe et al.
2012). A complicating factor is the identification of sec-
ondary mutations in both wild-type and mutant EZH2 al-
leles in B-Cell lymphoma cells lines, which can cooperate
to confer resistance to EZH2 inhibitors (Baker et al. 2015;
Gibaja et al. 2016). This emphasizes the probability that
acquired resistance to EZH2 inhibitors will also occur in
patients. Thus, alternative targets to disrupt both wild-
type andmutant EZH2 in cancerwill be needed. The devel-
opment of potent EED inhibitors, which block its ability to
allosterically activate PRC2 via its engagement with
H3K27me3, might help to bypass this complication (He
et al.2017;Qiet al. 2017). Importantly, cell lines thathadde-
veloped resistance to EZH2 SET domain inhibitors re-
mained sensitive to this EED inhibitor, indicating that
they may help to circumvent primary acquired resistance.
However, an alternative strategymay be needed to treat pa-
tients with T-ALL and MPNST that harbor loss-of-func-
tion mutations in PRC2. In the context of the chromatin
balance paradigm (Fig. 7A), it is tempting to speculate that
specific inhibitors of SWI/SNFmight open upnew opportu-
nities for treatment of these cancer types. In conclusion,
the detailed knowledge of the molecular mechanisms and
biologyof chromatin remodelers and Polycombs, is nowen-
abling the development of promising new therapeutic ap-
proaches to treat many human cancer types.
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